key: cord-0781651-m05fy8hc
authors: Javanmardi, Kamyab; Chou, Chia-Wei; Terrace, Cynthia; Annapareddy, Ankur; Kaoud, Tamer S.; Guo, Qingqing; Lutgens, Josh; Zorkic, Hayley; Horton, Andrew P.; Gardner, Elizabeth C.; Nguyen, Giaochau; Boutz, Daniel R.; Goike, Jule; Voss, Will N.; Kuo, Hung-Che; Dalby, Kevin N; Gollihar, Jimmy D.; Finkelstein, Ilya J.
title: Rapid characterization of spike variants via mammalian cell surface display
date: 2021-03-30
journal: bioRxiv
DOI: 10.1101/2021.03.30.437622
sha: beb6cd4943dc1a6440e76f22b0aa70d3722d4f6f
doc_id: 781651
cord_uid: m05fy8hc

The SARS-CoV-2 spike (S) protein is a critical component of subunit vaccines and a target for neutralizing antibodies. Spike is also undergoing immunogenic selection with clinical variants that increase infectivity and partially escape convalescent plasma. Here, we describe spike display, a high-throughput platform to rapidly characterize glycosylated spike ectodomains across multiple coronavirus-family proteins. We assayed ~200 variant SARS-CoV-2 spikes for their expression, ACE2 binding, and recognition by thirteen neutralizing antibodies (nAbs). An alanine scan of the N-terminal domain (NTD) highlights a public class of epitopes in the N3 and N5 loops that are recognized by most of the NTD-binding nAbs assayed in this study. Some clinical NTD substitutions abrogate binding to these epitopes but are circulating at low frequencies around the globe. NTD mutations in variants of concern B.1.1.7 (United Kingdom), B.1.351 (South Africa), B.1.1.248 (Brazil), and B.1.427/B.1.429 (California) impact spike expression and escape most NTD-targeting nAbs. However, two classes of NTD nAbs still bind B.1.1.7 spikes and neutralize in pseudoviral assays. B.1.1351 and B.1.1.248 include compensatory mutations that either increase spike expression or increase ACE2 binding affinity. Finally, B.1.351 and B.1.1.248 completely escape a potent ACE2 peptide mimic. We anticipate that spike display will be useful for rapid antigen design, deep scanning mutagenesis, and epitope mapping of antibody interactions for SARS-CoV-2 and other emerging viral threats.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the COVID-19 pandemic, causing >127 million infections and >2.7 million deaths worldwide (as of 28 The large reservoir of diverse and endemic coronaviruses in animals, and their frequent zoonotic transmission, suggests that future human outbreaks are inevitable 5, 6 .

Coronaviruses infect cells via attachment of viral transmembrane spike (S) glycoproteins 7 . SARS-CoV-2 spike interacts with angiotensin-converting enzyme 2 (ACE2) and other cell surface receptors to mediate fusion between the virus envelope and cell membrane [8] [9] [10] .

Spike homotrimers consist of the S1 and S2 functional subdomains 11 . After spike binds ACE2, structural rearrangements in the spike and cleavage by host proteases separate the S1 subunit from the S2 stalk 7 . The S2 stalk then undergoes further conformational changes that lead to membrane fusion and cell entry. The S1 subunit, which is composed of the N-terminal domain (NTD) and receptor-binding domain (RBD) 11 , is the key determinant of tissue and host tropism 7 .

Humoral immunity to the spike glycoprotein is the most potent means of protection from SARS-CoV-2 12 . SARS-CoV-2 vaccines generate a strong polyclonal antibody response by delivering spikes via immunization [13] [14] [15] . Spike is also the primary target for prophylactic and therapeutic neutralizing monoclonal antibodies (nAbs) and ACE2 binding inhibitors 16-20 . However, spike continues to mutate and recombine, establishing new variants for immunogenic selection 21 . Multiple variants of concern (VOCs) have increased viral transmissibility and antibody escape 6, 21 . Since the emergence of a globally dominant D614G mutation 22-24 , newer VOCs with compound spike mutations have taken hold. The B.1.1.7 (United Kingdom) 25 29 lineages are of particular concern because they partially evade monoclonal antibodies, convalescent sera, and vaccine-induced humoral immunity 30 . The antigenicity and infectivity of new virus variants are often assayed via live virus, pseudotyped viruses, and animal protection experiments. These assays are low throughput and require lengthy viral preparations 27 .

Cell surface display of the spike protein or its sub-domains is a high-throughput platform approach to functionally characterize key aspects of SARS-CoV-2 variants 31, 32 . For example, Starr et. al. and others have expressed the RBD on the surface of yeast cells to measure the subdomain expression, ACE2 binding affinity, and RBD-targeting nAb escape 19, [33] [34] [35] [36] . However, all spike VOCs include critical mutations that are outside the RBD. Moreover, the humoral immune response produces potent neutralizing antibodies that target the NTD as well as the RBD. Here, we describe a new experimental platform that measures spike expression, receptor binding, and antibody escape across variant spike homotrimers on the surface of mammalian cells.

Spike display is a rapid and high-throughput platform to characterize spike glycoproteins from diverse coronavirus families. Complex spike variants are assembled via a Golden Gate cloning framework, suitable for both manual and robotically automated cloning. The resulting spikes are displayed on the surface of mammalian cells and assayed via flow cytometry.

Cleaving spikes from cell surfaces further accelerates structural and biophysical characterization.

Using this platform, we mapped an NTD supersite that is recognized by the majority of NTD- escape the ACE2-mimetic LCB1 peptide, suggesting that micropeptide inhibitors must be updated or used as part of a multi-component inhibitor cocktail 16 . We anticipate that spike display will accelerate rapid antigen design, deep scanning mutagenesis, structural characterization of spike-antibody interactions, and antibody discovery to aid ongoing and future pandemic countermeasures.

We express the SARS-CoV-2 spike ectodomain on the surface of human embryonic kidney (HEK293T) cells. Six proline substitutions stabilize the homotrimeric complex in the pre-fusion state, along with the globally dominant D614G mutation (termed 6P-D614G) 22, 24, 37 . Spike is 5 directed to cell membranes via an N-terminal Ig Kappa secretion signal and a C-terminal PDGFR-β transmembrane domain 38 . The 58 amino acid (aa) flexible linker includes a triple FLAG (3xFLAG) epitope tag as a proxy for expression, a StrepII tag for purification, and a 3C protease cleavage site (Fig. 1a) . Immunostaining of fixed cells shows that spike is displayed on cell membranes ( Fig. 1b and Supplementary Fig. 1) . We confirmed the native homotrimeric assembly via negative-stain electron microscopy (nsEM) of spikes that were cleaved from the cell surface by 3C protease (Fig. 1c) . Two-dimensional class averages indicate that >99% of the surface-displayed spikes are in the pre-fusion conformation, with the majority (71%) of the particles having one receptor-binding domain (RBDs) up ( Supplementary Fig. 3 ). These results are consistent with previous assessments of HexaPro (6P) and D614G spike RBD up-down equilibrium 11,23,37 .

We assessed spike expression and antigenicity via flow cytometry. SARS-CoV-2 spike variants and related spike homologs were rapidly constructed via Golden Gate assembly from standardized parts and acoustic liquid handling ( Fig. 1a and Supplementary Fig. 2 and Methods).

Each variant was transfected into HEK293T cells and stained with anti-FLAG and fluorescent secondary (anti-mouse) antibodies. Mutant SARS-CoV-2 spike expression on the surface of mammalian cells strongly correlated with the relative expression of recombinant spike mutants ( Fig. 1d) 24, 37 . The relative expression of spikes from related betacoronaviruses SARS-CoV-1, MERS, and HKU1 also followed the relative stabilities of their recombinant proteins (Supplementary Fig. 5 ) 11, 37, 39, 40 . We conclude that spike display can be used for the rapid assessment of structural expression of coronavirus spike variants and for designing nextgeneration pre-fusion stabilized vaccine targets.

Next, we measured ACE2 binding affinity of surface-displayed spikes. Non-cross reactive fluorescent secondary antibodies were directed against the human (ACE2 binding) and mouse Fc (anti-FLAG; spike expression). This two-color assay enables spike expression-based signal normalization for antigen binding ( Fig. 1e and Supplementary Fig. 4 ). As expected, SARS-CoV-1, SARS-CoV-2 and the isolated RBD avidly bound ACE2, whereas spike(∆RBD) did not bind ACE2 above background. The higher affinity of SARS-CoV-2 relative to CoV-1 spike is consistent with prior in vitro measurements with purified proteins 11 . The MERS and HKU1 spikes recognize the human DPP4 receptor and 9-O-acetylated sialic acids respectively, and have no affinity for ACE2 41 .

6 Spike display enables rapid flow cytometry-based characterization of neutralizing antibodies (nAbs) 31 . An estimated 10% of the nAbs in seroconverted COVID-19 patients bind outside of the RBD and many RBD-binders may bind across multiple subunits 17, 42, 43, 31 . Therefore, we assayed nAb binding to different spike sub-domains. We first tested REGN10987, 4A8, and 2-43 which are RBD-, NTD-, and S1 (quaternary)-binding nAbs, respectively ( Fig.   1f ) [42] [43] [44] . The signal generated from human-Fc binding secondary antibodies was normalized to the spike expression signal, enabling accurate binding measurements (see Methods). We observed domain-specific nAb binding with full spikes, whereas the RBD alone only bound REGN10987. We next measured quantitative binding affinities of seven NTD-binding nAbs via surface display (Fig. 1g) . We selected nAbs that bind with pM to ~10 nM binding affinities.

These peripheral blood mononuclear cell (PBMC) derived antibodies were identified through diverse discovery platforms, including Ig-seq 45 , and exhibited differing neutralization potencies and NTD binding epitopes. The binding affinities derived from fitting the sigmoidal titration curves corresponded closely to the affinities measured with recombinant proteins (Supplementary Fig. 6 and Table S1 ). Titration experiments with ACE2, the REGN-COV2 cocktail nAbs (REGN10933 and REGN10987, both binding the RBD), and 2-43 (S1 binder) confirmed that spike display is a quantitative platform for measuring antibody and antigenbinding affinities. (Fig. 1h) . Assaying nAb binding on full-length spike ectodomains (S-ECD) will thus be a valuable tool for rapid antibody discovery and characterization.

The SARS-CoV-2 spike NTD elicits high affinity neutralizing antibodies in seroconverted patients 42, 43, 46 . However, our analysis of the GISAID database of SARS-CoV-2 genomes indicated that 46% of all spike protein mutations (399,299 out of 866,373 total; accessed on 24/Feb/2021) are in the NTD-two-fold higher than a random distribution (expected to be 23%) ( Fig. 2a, Supplementary Fig. 7 , and Methods) 47 . The high number of NTD mutations in clinical samples raises the possibility of selective immune pressure and subsequent escape. To elucidate the mechanisms for binding and neutralization, we focused on ten neutralizing NTD-directed antibodies, six of which had their epitopes mapped via cryo-EM 42, 43, 46, 48 . Notably, 4A8, CM25, and 4-8 bind loops N3 (residues 141 to 156) and N5 (residues 246-260), suggesting that these may be public epitopes 48, 49 . Therefore, we cloned 44 alanine spike mutants that encompass N3, 7 N5, and adjacent residues (Fig. 2b) . Alanine NTD substitutions very mildly destabilized spike expression ( Supplementary Fig. 8 ). We tested this alanine library against the ten NTD nAbs described above, along with the RBD-binding ACE2 and REGN10987 as negative controls.

We first focused on 4A8, which interacts with eight residues in the N3 and N5 loops of the NTD 42 . Unexpectedly, only three of these substitutions-Tyr145, Lys147, and Trp152reduced antibody binding >5-fold ( Fig. 2c and 2d) . Combining any two of these substitutions resulted in an additional loss of binding, sometimes to below the detection limit (Fig. 2e) .

Surprisingly, two close contacts observed in the 4A8 Fab-spike ectodomain structure are dispensable for strong binding. Lys150, which forms a salt bridge with 4A8, only minimally reduced binding affinity. Arg246 on the N5 loop, which is buried in the 4A8-spike interface, reduced binding a modest 0.8-fold. Antibodies CM17, CM25, and 1-68 were also sensitive to alanine substitutions at Tyr145, Lys147, and Trp152, suggesting that they recognize the same NTD epitope as 4A8 46 . Despite competing with 1-68 in a spike binding assay, 1-87 showed little to no loss in binding from any single-alanine substitution in our library. We speculate that the CDR-1 and -3 of the 1-87 are minimally impacted by single alanine substitutions at the NTD surface. Antibodies 5-7 and 4-19, which competes with 1-87 binding on the NTD, were more sensitive to substitutions in the N1 loop (residues 14-26) and a region between the N3 and N4 loops. All three of these nAbs have weaker neutralizing IC50's (5-7 = 0.033 μg mL -1 , 1-87 = 0.086 μg mL -1 , and 4-19 = 0.109 μg mL -1 ) relative to nAbs which showed strong N3 loop binding (4-8 = 0.009 μg mL -1 , 1-68 = 0.014 μg mL -1 IC50s), suggesting that the N3 loop plays an important role in NTD mediated spike neutralization 43 . Spike display complements structural studies and Fab competition assays by providing high-resolution epitope maps and by reporting affinity changes as a consequence of amino acid substitutions.

Guided by the alanine scan results, we profiled 46 non-synonymous NTD mutants for their impact on spike expression and antibody evasion. All NTD mutants retained wildtype levels of ACE2 binding and spike expression (Fig. 3a) . Substitutions at Tyr145 strongly reduced 4A8 binding, as highlighted by the alanine scan. These polar and charged residues (Asn, Asp, and His) likely disrupt the hydrophobic and/or π/π interactions with 4A8's CDR-3 region.

Substitutions at Tyr145 also reduced binding of CM17, CM25, and 1-68 to spike. Consistently, 8 positions shown to be critical for antibody binding in the alanine scan were also sensitive to different amino acid substitutions. Notably, NTD variants that reduced nAb binding >16-fold appeared at very low frequencies (<0.001) in the GISAID database. Two noteworthy exceptions include M153T and S254F, both of which show strong escape from CM30 ( Fig. 3b and Supplementary Fig. 9 ) 47 .

Pearson correlation analysis of the NTD alanine and clinical variant binding data showed strong similarities between NTD binding nAbs and no correlation with REGN10987 ( Fig. 3c and Supplementary Fig. 10 ). We clustered antibodies into four primary groups based on Pearson correlation (r) values (>0.5) between their relative binding affinities for the alanine and clinical spike mutants. The largest group consists of 4A8, 1-68, 1-87, CM17, and CM25, all of which genetically originate from the VH1-24 multi-donor class of antibodies 46, 48 . Interestingly, some antibodies derived from VH3-30 (4-18) have overlapping epitopes with VH1-24 derived nAbs but have significantly different binding modes 48 . ELISA competition assays have implicated distinct binding epitopes for 5-7 and 4-19 compared to the other antibodies in this set 43 .

Deletions and insertions in NTD loops N3 and N5 are also possible routes for immune evasion ( Fig. 3d) 50, 51 . A lab-evolved SARS-CoV-2 virus with an 11 amino acid insertion in N5

[248aKTRNKSTSRRE248k] evaded high titer convalescent sera 52 . To clarify the escape mechanisms, we assayed these variants against the panel of nAbs described above (Fig. 3e) .

Deletions within the N3 loop (Phe140-Leu141, Tyr144/145, and His146) disrupted binding to most NTD nAbs. A deletion at Phe140, located at the base of the N3 loop, also caused a moderate loss in binding for most of the NTD-binding antibodies. Similarly, a deletion at the base of the N5 loop (Ala243-Leu244) and an 11 amino acid insertion within the N5 loop resulted in reduced binding for most of the nAbs (Fig. 3e) . A deletion at Ile210 had negligible effects on antibody binding. Together, these results suggest that indels within or adjacent to the N3 and N5 loops effectively abrogate nAb binding, likely due to the deletion of critical residues or spatial reconfigurations of the NTD loops. An insertion in the N5 loop also effectively evades neutralizing antibodies. As immune escape becomes a major evolutionary factor in an increasingly vaccinated world, NTD insertions may also become more common.

Next, we examined RBD mutations, eleven of which were previously reported to escape therapeutic antibodies from the REGN-COV2 cocktail (REGN10933 and REGN10987) (Supplementary Fig. 11 ) 34 . Expression of the full spike trimers and their escape from RBD-binding nAbs correlated well with changes in expression for the RBD alone (Supplementary Fig. 11a-e). However, K417N strongly reduced ACE2 binding in the context of the full spike relative to the isolated RBD. Similarly, F486K reduced REGN10933 binding relative to the RBD-only yeast display. Both K417 and F486 are buried and sterically occluded when the RBD is in the "down" position, providing a possible explanation for a larger reduction in binding observed with spike display compared to yeast display ( Supplementary Fig. 11f) . We also examined a quaternary S1-binding nAb and the NTD binder 4A8. As expected, 4A8 binding was not affected by RBD mutations. Three variants (L455A, F486K, and E406W) that reduced REGN10933 binding also reduced 2-43 binding ( Supplementary Fig. 11b ). These findings underscore the importance of characterizing nAb escape mutations within the context of the fully glycosylated spike trimer.

We quantified spike expression, ACE2 affinity, and immune evasion in VOCs (Fig. 4) . ACE2 mimics are promising SARS-CoV-2 inhibitors but many were designed against the viral clades circulating in 2019. Their efficacy has not been assessed with modern VOCs 16, 18 .

We, therefore, tested how the VOCs bind LCB1, an engineered alpha-helical peptide that competes with ACE2 for binding to the RBD 16 . LCB1 has a sub-nM affinity for the RBD in vitro and neutralizes live viruses with an IC50 of 24 pM 16 . We developed a competition assay where cells are co-incubated with increasing concentrations of LCB1 and a fixed ACE2 concentration.

Changes in ACE2 binding were then measured by flow cytometry (Fig. 4k) . Variant B.1.1.7

showed the same sigmoidal curve as WT (6P-D614G) spike, indicating potent inhibition of ACE2 binding above > 1nM LCB1 (Fig. 4m) binding affinity (Fig. 4l) . Future peptide-based inhibitor therapies will require a cocktail of inhibitors to evade VOCs. Alternatively, these peptides must be continually optimized to improve efficacy against emerging viral variants 19 .

We developed spike display to accelerate vaccine design and to rapidly assess the effects of mutations in emerging virus strains. Pre-fusion stabilized spike is the primary antigen delivered via immunization. Pre-fusion stabilization requires laborious biochemical assays following structure-guided selection of promising stabilizing mutations 11,37,39,56 . Spike display shortens this workflow by rapidly assessing the expression of individual point mutants and their combinatorial derivatives (Fig. 1d) . Cleaving the spikes from cell surfaces facilitates preliminary structural and biophysical characterization. We anticipate that spike display can be adapted for diverse coronavirus-family spikes and other viral antigens (Fig. 1e ) 31,57,58 .

Spike display also complements structure-function studies for high-resolution epitope mapping. We focused on the NTD because it is under heavy mutational pressure in circulating SARS-CoV-2 variants and elicits neutralizing antibodies in convalescent patients 42, 43, 46, 49, 59 . Our NTD scan uncovered that most of the NTD-binding nAbs recognize a public epitope comprised of the N3/N5 loops. Using this epitope map, we identified circulating virus variants that escape NTD-binding nAbs. We conclude that the NTD is under strong evolutionary pressure and that NTD-targeting therapeutic nAb cocktails must also target other epitopes to avoid therapeutic evasion. Spike display accelerates the characterization of antibody-spike interactions and the consequences of non-synonymous spike mutations on these interactions. The entire process, from Golden Gate assembly to flow-based characterization can be completed in < 5 days.

Downstream biophysical studies can use the cell-cleaved spikes without laborious recombinant protein purification. A second-generation spike display platform will increase throughput by integrating spike variants in a chromosomal locus and sorting pooled libraries for phenotypic differences [63] [64] [65] . Increasing throughput will allow interrogation of all circulating nonsynonymous spike mutations and rapid protein engineering for pre-fusion stabilization. Deep mutational scanning of all possible amino acid substitutions will be broadly useful for characterizing the spike mutational landscape as well as discovering invariant pan-coronavirus epitopes and vaccine antigens. 

Oligonucleotides and gene blocks were purchased from Integrated DNA Technologies (IDT).

Restriction enzymes, polymerases, and ligases were purchased from New England Biolabs (NEB). Antibodies were purified as described below or purchased from the following 

Spike display plasmids incorporate the pre-fusion stabilized SARS-CoV-2 S-6P ("HexaPro") as the reference sequence for all spike variants (Addgene #154754) 37 . This construct comprises residues 1-1208 of SARS-CoV-2 S gene (GenBank: MN908947) with prolines substituted at residues F817, A892, A899, A942, K986, V987, a protease-inactive furin cleavage site ( 682 GSAS 685 ), and the globally dominant D614G mutation 22 . This construct (6P-D614G) was optimized for mammalian cell surface display and high throughput Golden Gate cloning as described below.

For mammalian surface display, spike was cloned into a pcDNA5-based vector (Addgene #113547) with the following additional N-terminal Ig-Kappa leader and C-terminal epitopes ordered as two separate gBlocks (IDT): a 3X-FLAG, a Strep Tag II epitope, an HRV 3C protease site, and a PDGFR- transmembrane domain. All three parts (N-terminal leader, spike, and Cterminal additions) were assembled with the pcDNA5 backbone using Hi-Fi DNA assembly (NEB; E2621S).

To enable high throughput Golden Gate cloning of cell surface-displayed spike variants, the spike coding region was divided into 5 parts with junctions strategically positioned at amino acids with low mutational frequencies, according to the GISAID. For each of the 5 parts, an entry vector was constructed by cloning in a superfolder GFP (sfGFP) bacterial expression cassette with flanking AarI cut sites and unique 4 nt overhangs matching the wild-type SARS-CoV-2 sequence of each part junction, using PCR and Hi-Fi DNA assembly (See Supplementary   Fig. 2) . A part 1-5 entry vector was made with the entire SARS-CoV-2 coding sequence replaced with the sfGFP cassette to enable multi-part assemblies of complex spike variants or entirely different spike proteins. Parts 1,2,3,4, and 5 of the 6P-D614G coding sequence were PCR amplified with flanking AarI cut sites, the matching 4 nt overhangs for spike assembly (See Supplementary Fig. 2) , Esp3I cut sites, and 4 nt overhangs for YTK001 assembly. The Esp3I (NEB; R0734) and adjacent 4 nt overhangs were used to incorporate, via Golden Gate cloning, each part (1-5) coding sequences into the YTK001 entry vector from the yeast toolkit 67 .

Golden Gate constructs were assembled using a high-throughput automated pipeline that Outgrown cells were plated dropwise on Nunc OmniTrays (5 μL per plate) (Thermo Fisher; 140156), containing LB-agar + carbenicillin at 100 µg/mL. Each plate can fit 96, 5 µL drops. Plates were kept at room temperature until the drops dried and were then transferred to a 37 °C incubator for growth overnight (12-16 hours) .

Colonies were screened the following day and picked using the QPix 420, selecting only white colonies and avoiding green fluorescent colonies, which still contain the sfGFP cassette and not the desired spike sequence. Colonies were picked into 1 mL of SB media with antibiotic in Axygen deep well grow blocks and grown overnight at 37 °C while shaking. Once grown, liquid cultures were pelleted at 3000 g for 10 minutes and miniprepped using the Tecan Fluent robotic liquid handler with Promega Wizard SV 96 Plasmid DNA Purification Kit (Promega; A2250).

Previously published VH and VL sequences were purchased as gBlocks (IDT) to create fulllength antibody IgGs [42] [43] [44] . VHs and VLs were cloned into custom Golden Gate compatible pcDNA3.4 vectors for IgG1 expression. 

Human ACE2-Fc was recombinantly expressed in Expi293 cells with minor modifications to previously published protocols 11 . Simply, the ACE2-Fc expression vector was transfected into

Expi293T cells according to the manufacturer's instructions (Sigma-Aldrich; L3287). Five days after transfection the supernatant was collected by first spinning cultures at 300 g for 5 min at 4°C. Cell debris and supernatant were further separated by spinning at 10,000 g for 20 min at 4°C. Upon resuspending in PBS, ACE2-Fc was purified over Protein A Agarose (Thermo Fisher; 15918014). Once the Protein A Agarose was equilibrated in PBS buffer, the respective supernatant was applied 3X and washed with 10 bed volumes of PBS buffer. The protein was eluted with 100mM glycine-HCL (pH 2.4) into 0.1X volume Tris buffer (pH 8.5) and 100 mM NaCl. Purified ACE2-Fc was stored at 4 °C for short-term storage, and frozen at -20 °C for longterm storage.

Plasmids were transfected into Expi293 cells and expressed as described previously 37 

Most of the plasmids needed for expressing the HIV virion under the CMV promoter were obtained from BEI resources, including HDM-Hgpm2, pRC-CMV-Rev1b, and HDM-tat1b (BEI catalog numbers NR-52516, NR-52519, and NR-5251, respectively) 68 . The lentiviral backbone plasmid, expressing a luciferase reporter under the CMV promoter followed by an IRES and ZsGreen, was also provided by the BEI resources (NR-52520 column. After spin concentrating the elution fractions to 1 mL, spikes were further purified by size-exclusion chromatography using a Superose 6 Increase 10/300 column (GE Healthcare).

Purified SARS-CoV-2 spike variants were diluted to a concentration of 40 μg mL -1 in 50 mM

Tris-HCL pH 8.0 and 150 mM NaCl. CF400-CU grids (Electron Microscopy Science) were cleaned in a Gatan Solarus 950 plasma cleaner for 45 seconds. Spikes were deposited on the girds and stained with Nano-W ® (Methylamine Tungstate). Grids were then imaged on a Talos F200C TEM microscope equipped with a Ceta 16M detector (Thermo Fisher). 106 micrographs were imaged from a single grid at a magnification of 92000X, corresponding to a calibrated pixel size of 1.63 Å/pix. Motion correction, CTF estimation and particle picking were performed in CisTEM 69 . Particle stacks were then imported into cryoSPARC v3.1.0 for 2D classification, ab initio 3D reconstruction, heterogeneous 3D refinement, and homogeneous 3D refinement 70 .

After Cleavage with 3C protease, supernatants containing spikes variants were diluted 2-fold with BLI buffer composed of 10 mM HEPES pH 7.5, 150 mM NaCl, 3 mM EDTA, 0.05% v/v Surfactant P20, 1 mg/mL bovine serum albumin. Analytes were also serial diluted with BLI buffer. Anti-mouse Fc capture (AMC) biosensor (FortéBio) were hydrated with BLI buffer for 10 mins in an Octet RED96e (FortéBio). Then, anti-FLAG IgG which is produced by mouse was immobilized to the AMC sensor tip. The assay went through the following steps: 1) baseline: 60 s with BLI buffer; 2) IgG immobilizing: 360 s with anti-FLAG IgG; 3) spikes loading: 360 s with diluted supernatants; 4) baseline: 300 s with BLI buffer; 5) association: 600 s with serial diluted analytes (antibodies or ACE2); 6) dissociation: 600 s with BLI buffer. The data were reference-subtracted and analyzed by Octet Data Analysis software v11.1 using steady-state analysis. All structures (7DDN 66 , 7C2L 42 , and 7JZL 16 ) were downloaded from the RCSB-PDB as PDB files and imported into ChimeraX 1.1 for visualization and image creation.

To identify and obtain SARS-CoV-2 spike protein variants of interest, we performed pairwise sequence alignment of all spike proteins in the GISAID EpiCoV database and the SARS-CoV-2 reference sequence with the genbank number BCN86353.1 47 . We downloaded all published spike protein sequences from the GISAID (accessed on 2/24/2021) as a FASTA file. We then used the Biopython Bio.SeqIO package (https://biopython.org/wiki/SeqIO ) to extract the spike protein amino acid sequence and related species information from each entry in the FASTA file.

Preliminary filtering was performed to remove non-human sequences, sequences with more than 800 unknown amino acid sequences ("X"), and sequences with <1250 or >1280 amino acids.

484,744 out of the 606,304 sequences passed these filters. GB number BCN86353.1 47 .

We then used the python parasail package (https://github.com/jeffdaily/parasail-python)

to perform a semi-global alignment of each sequence to the reference sequence 71 . Parameters were set to no penalties for gaps at the beginning and end of both sequences using a BLOSUM80 substitution scoring matrix, a gap opening penalty of 5 within the sequence, and a gap extension penalty of 2 within the sequence. A BLOSUM80 scoring matrix was used because higher number blosum matrices (blosum80 as opposed to blossom32) compare closely related sequences. The highest scoring sequence alignment was kept and the aligned sequence was compared position-wise to the reference sequence to identify insertions, deletions, and substitutions. Frequencies of each unique substitution, insertion, and deletion were obtained with the following equation: frequency = ∑(sequences containing each mutation) ÷ ∑( all sequences aligned)

Data analysis was performed with the R tidyverse package and ggplot2 72 .

The means ± S.D. were calculated and reported for all appropriate data. NTD-targeting nAbs were group based on Pearson correlation r values >0.5.

Comparative Review of SARS-CoV-2, SARS-CoV, MERS-CoV, and Influenza A Respiratory Viruses

Middle East respiratory syndrome

The Severe Acute Respiratory Syndrome

Characterization and Complete Genome Sequence of a Novel Coronavirus, Coronavirus HKU1, from Patients with Pneumonia

Spillover and pandemic properties of zoonotic viruses with high host plasticity

Emergence of SARS-CoV-2 through recombination and strong purifying selection

Structure, Function, and Evolution of Coronavirus Spike Proteins

Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target

Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity

Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Correlates of protection against SARS-CoV-2 in rhesus macaques

DNA vaccine protection against SARS-CoV-2 in rhesus macaques

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

De novo design of picomolar SARS-CoV-2 miniprotein inhibitors

Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2

Engineering human ACE2 to optimize binding to the spike protein of SARS coronavirus 2

De novo design of potent and resilient hACE2 decoys to neutralize SARS-CoV-2

An engineered decoy receptor for SARS-CoV-2 broadly binds protein S sequence variants

Recombination events are concentrated in the spike protein region of Betacoronaviruses

Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G

Increases Infectivity of the COVID-19 Virus

Structural and Functional Analysis of the D614G SARS-CoV-2

Molecular Architecture of Early Dissemination and Massive Second Wave of the SARS-CoV-2 Virus in a Major Metropolitan Area

Estimated transmissibility and impact of SARS-CoV-2 lineage

Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-2 in the United Kingdom

Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7

SARS-CoV-2 variants B.1.351 and B.1.1.248: Escape from therapeutic antibodies and antibodies induced by infection and vaccination

Transmission, infectivity, and antibody neutralization of an emerging SARS-CoV-2 variant in California carrying a L452R spike protein mutation

Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity

Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding

Human cytomegalovirus-specific T-cell receptor engineered for high affinity and soluble expression using mammalian cell display

Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition

Prospective mapping of viral mutations that escape antibodies used to treat COVID-19

Mutational escape from the polyclonal antibody response to SARS

CoV-2 infection is largely shaped by a single class of antibodies

One-shot identification of SARS-CoV-2 S RBD escape mutants using yeast screening

Structure-based design of prefusion-stabilized SARS-CoV-2 spikes

Stable, high-affinity streptavidin monomer for protein labeling and monovalent biotin detection

Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen

Pre-fusion structure of a human coronavirus spike protein

Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine

A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2

Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike

Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail

Next-generation sequencing and protein mass spectrometry for the comprehensive analysis of human cellular and serum antibody repertoires

Prevalent, protective, and convergent IgG recognition of SARS-CoV-2

non-RBD spike epitopes in COVID-19 convalescent plasma

Data, disease and diplomacy: GISAID's innovative contribution to global health

Potent SARS-CoV-2 Neutralizing Antibodies Directed Against Spike N-Terminal Domain Target a Single Supersite

N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2

An infectivity-enhancing site on the SARS-CoV-2 spike protein is targeted by COVID-19 patient antibodies

Recurrent deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape

SARS-CoV-2 escape in vitro from a highly neutralizing COVID-19 convalescent plasma

Diversity of Functionally Permissive Sequences in the Receptor-Binding Site of Influenza Hemagglutinin

Extraepitopic Compensatory Substitutions Partially Restore Fitness to Simian Immunodeficiency Virus Variants That Escape from an Immunodominant Cytotoxic-T-Lymphocyte Response

Permissive Secondary Mutations Enable the Evolution of Influenza Oseltamivir Resistance

Stabilizing the Closed SARS-CoV-2 Spike Trimer

Development of a novel mammalian cell surface antibody display platform

Mammalian cell surface display for monoclonal antibody-based FACS selection of viral envelope proteins

Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein

Sequence Analysis of 20,453 SARS-CoV-2 Genomes from the

Houston Metropolitan Area Identifies the Emergence and Widespread Distribution of Multiple Isolates of All Major Variants of Concern

Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera

Transmission of SARS-CoV-2 Lineage B.1.1.7 in England: Insights from linking epidemiological and genetic data

An improved platform for functional assessment of large protein libraries in mammalian cells

Multiplex assessment of protein variant abundance by massively parallel sequencing

A Multiplexed Assay for Exon Recognition Reveals that an

Unappreciated Fraction of Rare Genetic Variants Cause Large-Effect Splicing Disruptions

Development and structural basis of a two-MAb cocktail for treating SARS-CoV-2 infections

A Highly Characterized Yeast Toolkit for Modular, Multipart Assembly

Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS-CoV-2 Spike Protein for Neutralization Assays

user-friendly software for single-particle image processing

cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination

SIMD C library for global, semi-global, and local pairwise sequence alignments

Welcome to the Tidyverse